MIRA Pharmaceuticals Inc. (NASDAQ: MIRA) initiated dosing in the final cohort of its Phase 1 clinical trial for Ketamir-2, an ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE